Skip to content

Study for the innovative clinical protocol and application of treating gastric cancer by the rule of ''the body and spirit, stasis, toxin and depression together''

Study for the innovative clinical protocol and application of treating gastric cancer by the rule of ''the body and spirit, stasis, toxin and depression together''

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033191
Enrollment
Unknown
Registered
2020-05-23
Start date
2020-06-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Sponsors

Affiliated Cancer Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patients with TNM stage III gastric cancer were diagnosed by pathology, and D2 radical operation had been performed, and chemotherapy had not been started; 2. The syndrome differentiation of traditional Chinese medicine is the syndrome of stasis, toxin and depression; 3. Patients aged 18 to 75 years; 4. Patients with good general condition and ECoG score <=2; 5. The subjects must have informed consent before the test, fully understand the test content, process and possible adverse reactions, and sign the written informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with gastric cancer metastasis or recurrence, or with other tumors within 5 years; 2. Patients with expected survival time <=3 months; 3. Patients with severe malnutrition, primary diseases of heart, brain, lung, liver, kidney, endocrine, blood, nervous system or other acute and chronic diseases that may significantly affect the treatment and prognosis; 4. Patients with history or risk of epilepsy; 5. Patients with dementia or severe mental disorder who cannot understand or express informed consent; 6. Current or previous patients with a history of alcohol or drug abuse or drug abuse; 7. Male subjects (or their partners) or female subjects have birth plans or egg donation plans within 28 days before screening and 6 months after the last administration of the study drug, and are unwilling to take one or more non drug contraceptive measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial period; 8. Pregnant, pregnant or lactating patients; 9. Patients who are participating in other clinical studies; 10. Patients who are allergic to the test drug and its components; 11. Patients who can not swallow tablets or traditional Chinese medicine decoction, malabsorption syndrome or any condition affecting gastrointestinal absorption; 12. Patients with active tuberculosis (TB) are receiving anti TB treatment or have received anti TB treatment within one year before screening; 13. Patients who were not considered suitable for the study.

Design outcomes

Primary

MeasureTime frame
1-year disease-free survival, DFS;

Secondary

MeasureTime frame
Quality of Life scale (QOL-C30);1-year survival rate: end point evaluation;Living ability score;Evaluation of weight change;Curative effect score of TCM syndrome;Pittsburgh Sleep quality score scale;Hamilton Depression scale;Hamilton anxiety scale;Completion rate and delay rate of chemotherapy;

Countries

China

Contacts

Public ContactZhang Guangji

Zhejiang Chinese Medical University

zgj@zcmu.edu.cn+86 13957152511

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026